Obesity is not a willpower problem.
It's a medical one.
If you've tried diets, cut portions, pushed through workouts — and still struggled — you weren't failing. Your biology was. Obesity is a chronic, progressive medical condition driven by hormones, brain chemistry, and metabolic adaptation. It deserves the same clinical rigour we give to diabetes or hypertension.
Your brain is defending your weight. That's not a metaphor.
Once obesity is established, the body adapts to protect it. Hunger signals increase. Energy expenditure drops. Weight regain is actively promoted at a biological level. This is why willpower alone has a near-zero long-term success rate — not because people aren't trying hard enough, but because the system is working against them.
Modern medicine is unambiguous: obesity is a chronic, relapsing metabolic disease. The 2025 Indian Obesity Commission recognises this, and so does Leanova. Treating it requires medical tools — not motivation posters.
Hypothalamic hunger regulation
Obesity alters the brain's set point for body weight. Leptin resistance means hunger signals remain elevated even after eating. The brain actively defends higher body weight.
Metabolic adaptation
Calorie restriction triggers compensatory drops in metabolic rate. The body burns fewer calories at rest — making sustained weight loss progressively harder without medical support.
Genetic and hormonal factors
Over 1,000 gene variants are associated with obesity risk. Thyroid dysfunction, insulin resistance, cortisol dysregulation, and PCOS all drive weight gain independent of behaviour.
Weight regain is biological, not personal
Studies consistently show that 80–95% of weight lost through dieting is regained within 5 years — not because of lack of willpower, but because of hormonal and neurological compensation.
The standard BMI chart wasn't built for you.
Global BMI thresholds were developed largely on Western population data. South Asians develop insulin resistance, visceral fat accumulation, and cardiovascular risk at significantly lower BMI values.
Global guidelines begin obesity at BMI ≥30. Indian guidelines recognise that metabolic complications begin earlier — and treatment should too. Learn more about BMI and Indian thresholds →
Obesity doesn't just live in the body.
People with obesity are significantly more likely to experience depression, anxiety, disordered eating, and low self-worth. This isn't coincidence — it's biology and stigma operating together.
Chronic systemic inflammation impairs neurotransmitter signalling. Elevated cortisol drives visceral fat accumulation and increases appetite. Weight-based discrimination activates shame, reduces care-seeking, and deepens isolation.
The relationship runs in both directions: obesity worsens mental health, and poor mental health worsens obesity. Any treatment that ignores this cycle will fail.
Breaking this cycle requires medical and psychological support — together, not as an afterthought. This is why psychological support at Leanova is built into the programme, not optional.
Even 5% makes a measurable difference.
Weight loss does not need to be dramatic to be meaningful. Improvements in metabolic health and quality of life begin at just 5% body weight reduction — and scale from there.
Blood pressure & glucose
Measurable improvements in blood pressure, blood glucose, and HbA1c control begin at just 5% weight loss.
Diabetes prevention & liver health
Type 2 diabetes prevention. Improved lipid profile. Liver fat reduction (MASLD). Better PCOS outcomes. Improved mood and self-esteem.
Cardiovascular protection
Reduced cardiovascular events. Improved knee osteoarthritis. Regression of liver disease (MASH). Sustained quality-of-life gains.
Diabetes remission
Type 2 diabetes remission. Reduced heart failure risk. Lower cardiovascular mortality. Documented even with minor subsequent regain.
Individual results vary. Medical assessment is required. These are population-level evidence summaries, not individual guarantees.
This is how the medicine works.
GLP-1 and GIP are incretin hormones released by the gut after eating. They regulate hunger, satiety, insulin secretion, and fat metabolism — the same systems hijacked by obesity. Incretin-based medications restore balance to these pathways, working with your biology rather than against it.
Brain
Activates hypothalamic satiety centres. Reduces hunger signals and food cravings at the source.
Stomach
Delays gastric emptying. Sustains fullness after meals, reducing the urge to eat again soon.
Pancreas
Stimulates insulin release in a glucose-dependent manner. Very low hypoglycaemia risk compared to older diabetes medications.
Fat Tissue
Improves insulin sensitivity at the cellular level. Reduces fat cell formation and promotes fat mobilisation.
Liver
Reduces hepatic glucose production. Promotes liver fat metabolism — important for Indians with high MASLD rates.
GLP-1 and GIP receptor agonists are prescription medications prescribed only after a full clinical assessment. Not every patient is eligible. Dosage and treatment pathway are determined entirely by your Leanova doctor — never self-selected. See how the programme works →
The benefits go far beyond weight.
Incretin-based therapies represent a paradigm shift in obesity medicine. Clinical trials demonstrate meaningful protection across multiple organ systems — independent of weight loss itself.
Heart health
Significant reduction in major adverse cardiovascular events — heart attack, stroke, and cardiovascular death. Improved blood pressure, LDL cholesterol, and systemic inflammation.
Kidney protection
GLP-1 therapies slow kidney function decline and reduce albuminuria. Clinical trials show they can delay or prevent kidney failure, dialysis, or transplant need — independent of glycaemic control.
Liver health
Regression of liver fat and prevention of liver scarring in MASLD and MASH — conditions disproportionately prevalent among Indians due to genetic predisposition.
Metabolic control
Highly effective reduction in blood glucose and HbA1c with very low hypoglycaemia risk. Demonstrated ability to prevent progression from prediabetes to Type 2 diabetes.
Sleep apnoea
Significant reduction in apnoea and hypopnoea events in clinical trials. Some patients no longer require CPAP after treatment — a major quality-of-life improvement.
Emerging research
Early evidence suggests potential benefits in Parkinson's disease motor decline, all-cause dementia incidence, and substance use disorders — through central reward pathway modulation.
Four pillars. One continuous treatment.
Effective obesity care is not a single intervention. International guidelines — AHA, ESC, and the Indian Obesity Commission — are unequivocal: obesity requires medical, nutritional, behavioural, and long-term maintenance support working in parallel.
Lifestyle Intervention
Medical Treatment (when indicated)
Metabolic Optimisation
Long-Term Maintenance
What the evidence actually says.
These are not opinions. They are the clinical positions of global and Indian medical bodies — summarised plainly.
Your body deserves medical care.
Your mind deserves compassion.
Leanova is a doctor-led metabolic treatment programme built for Indian adults — combining GLP-1 pharmacotherapy, culturally matched nutrition, and behavioural support. This is not a challenge. It's a treatment.
For educational purposes only. Treatment is prescribed by licensed medical professionals following clinical eligibility assessment. All medications are prescribed under direct physician supervision. Individual results vary. This page summarises published clinical evidence and does not constitute medical advice.
Obesity is not a willpower problem.
It's a medical one.
If you've tried diets, cut portions, pushed through workouts — and still struggled — you weren't failing. Your biology was. Obesity is a chronic, progressive medical condition driven by hormones, brain chemistry, and metabolic adaptation. It deserves the same clinical rigour we give to diabetes or hypertension.
Your brain is defending your weight. That's not a metaphor.
Once obesity is established, the body adapts to protect it. Hunger signals increase. Energy expenditure drops. Weight regain is actively promoted at a biological level. This is why willpower alone has a near-zero long-term success rate — not because people aren't trying hard enough, but because the system is working against them.
Modern medicine is unambiguous: obesity is a chronic, relapsing metabolic disease. The 2025 Indian Obesity Commission recognises this, and so does Leanova. Treating it requires medical tools — not motivation posters.
Hypothalamic hunger regulation
Obesity alters the brain's set point for body weight. Leptin resistance means hunger signals remain elevated even after eating. The brain actively defends higher body weight.
Metabolic adaptation
Calorie restriction triggers compensatory drops in metabolic rate. The body burns fewer calories at rest — making sustained weight loss progressively harder without medical support.
Genetic and hormonal factors
Over 1,000 gene variants are associated with obesity risk. Thyroid dysfunction, insulin resistance, cortisol dysregulation, and PCOS all drive weight gain independent of behaviour.
Weight regain is biological, not personal
Studies consistently show that 80–95% of weight lost through dieting is regained within 5 years — not because of lack of willpower, but because of hormonal and neurological compensation.
The standard BMI chart wasn't built for you.
Global BMI thresholds were developed largely on Western population data. South Asians develop insulin resistance, visceral fat accumulation, and cardiovascular risk at significantly lower BMI values.
Global guidelines begin obesity at BMI ≥30. Indian guidelines recognise that metabolic complications begin earlier — and treatment should too. Learn more about BMI and Indian thresholds →
Obesity doesn't just live in the body.
People with obesity are significantly more likely to experience depression, anxiety, disordered eating, and low self-worth. This isn't coincidence — it's biology and stigma operating together.
Chronic systemic inflammation impairs neurotransmitter signalling. Elevated cortisol drives visceral fat accumulation and increases appetite. Weight-based discrimination activates shame, reduces care-seeking, and deepens isolation.
The relationship runs in both directions: obesity worsens mental health, and poor mental health worsens obesity. Any treatment that ignores this cycle will fail.
Breaking this cycle requires medical and psychological support — together, not as an afterthought. This is why psychological support at Leanova is built into the programme, not optional.
Even 5% makes a measurable difference.
Weight loss does not need to be dramatic to be meaningful. Improvements in metabolic health and quality of life begin at just 5% body weight reduction — and scale from there.
Blood pressure & glucose
Measurable improvements in blood pressure, blood glucose, and HbA1c control begin at just 5% weight loss.
Diabetes prevention & liver health
Type 2 diabetes prevention. Improved lipid profile. Liver fat reduction (MASLD). Better PCOS outcomes. Improved mood and self-esteem.
Cardiovascular protection
Reduced cardiovascular events. Improved knee osteoarthritis. Regression of liver disease (MASH). Sustained quality-of-life gains.
Diabetes remission
Type 2 diabetes remission. Reduced heart failure risk. Lower cardiovascular mortality. Documented even with minor subsequent regain.
Individual results vary. Medical assessment is required. These are population-level evidence summaries, not individual guarantees.
This is how the medicine works.
GLP-1 and GIP are incretin hormones released by the gut after eating. They regulate hunger, satiety, insulin secretion, and fat metabolism — the same systems hijacked by obesity. Incretin-based medications restore balance to these pathways, working with your biology rather than against it.
Brain
Activates hypothalamic satiety centres. Reduces hunger signals and food cravings at the source.
Stomach
Delays gastric emptying. Sustains fullness after meals, reducing the urge to eat again soon.
Pancreas
Stimulates insulin release in a glucose-dependent manner. Very low hypoglycaemia risk compared to older diabetes medications.
Fat Tissue
Improves insulin sensitivity at the cellular level. Reduces fat cell formation and promotes fat mobilisation.
Liver
Reduces hepatic glucose production. Promotes liver fat metabolism — important for Indians with high MASLD rates.
GLP-1 and GIP receptor agonists are prescription medications prescribed only after a full clinical assessment. Not every patient is eligible. Dosage and treatment pathway are determined entirely by your Leanova doctor — never self-selected. See how the programme works →
The benefits go far beyond weight.
Incretin-based therapies represent a paradigm shift in obesity medicine. Clinical trials demonstrate meaningful protection across multiple organ systems — independent of weight loss itself.
Heart health
Significant reduction in major adverse cardiovascular events — heart attack, stroke, and cardiovascular death. Improved blood pressure, LDL cholesterol, and systemic inflammation.
Kidney protection
GLP-1 therapies slow kidney function decline and reduce albuminuria. Clinical trials show they can delay or prevent kidney failure, dialysis, or transplant need — independent of glycaemic control.
Liver health
Regression of liver fat and prevention of liver scarring in MASLD and MASH — conditions disproportionately prevalent among Indians due to genetic predisposition.
Metabolic control
Highly effective reduction in blood glucose and HbA1c with very low hypoglycaemia risk. Demonstrated ability to prevent progression from prediabetes to Type 2 diabetes.
Sleep apnoea
Significant reduction in apnoea and hypopnoea events in clinical trials. Some patients no longer require CPAP after treatment — a major quality-of-life improvement.
Emerging research
Early evidence suggests potential benefits in Parkinson's disease motor decline, all-cause dementia incidence, and substance use disorders — through central reward pathway modulation.
Four pillars. One continuous treatment.
Effective obesity care is not a single intervention. International guidelines — AHA, ESC, and the Indian Obesity Commission — are unequivocal: obesity requires medical, nutritional, behavioural, and long-term maintenance support working in parallel.
Lifestyle Intervention
Medical Treatment (when indicated)
Metabolic Optimisation
Long-Term Maintenance
What the evidence actually says.
These are not opinions. They are the clinical positions of global and Indian medical bodies — summarised plainly.
Your body deserves medical care.
Your mind deserves compassion.
Leanova is a doctor-led metabolic treatment programme built for Indian adults — combining GLP-1 pharmacotherapy, culturally matched nutrition, and behavioural support. This is not a challenge. It's a treatment.
For educational purposes only. Treatment is prescribed by licensed medical professionals following clinical eligibility assessment. All medications are prescribed under direct physician supervision. Individual results vary. This page summarises published clinical evidence and does not constitute medical advice.